Current:Home > reviewsAn experimental Alzheimer's drug outperforms one just approved by the FDA -WealthMap Solutions
An experimental Alzheimer's drug outperforms one just approved by the FDA
View
Date:2025-04-13 21:09:04
Patients in the early stages of Alzheimer's may soon have a new option to stave off the loss of memory and thinking.
In a study of more than 1,700 people, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%, scientists reported at the Alzheimer's Association International Conference in Amsterdam.
The result, published simultaneously in the journal JAMA, suggests that donanemab is at least as effective as the newly approved drug Leqembi (lecanemab), which was found to reduce progression by about 27%.
"This is the biggest effect that's ever been seen in an Alzheimer's trial for a disease-modifying drug," says Dr. Daniel Skrovonsky, director of research and development at Eli Lilly, which makes donanemab.
The company has submitted the results to the Food and Drug Administration and expects a decision by the end of the year.
But experts caution that donanemab is no cure, and that its benefit amounts to only about a seven-month delay in the loss of memory and thinking.
"I do think that will make a difference to people," says Dr. Reisa Sperling, who directs the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital in Boston. "But we have to do better."
Early treatment is key
Donanemab, like Leqembi, is a monoclonal antibody designed to remove a substance called beta-amyloid from the brain. Beta-amyloid tends to form sticky plaques in the brains of people with Alzheimer's.
The donanemab study focused on people whose brain scans showed plaques and other changes associated with early Alzheimer's. They had only mild cognitive symptoms.
Even within that group, though, people with more advanced disease saw less benefit from the drug.
"What we saw is that the ability to slow disease progression is strongest if you catch this disease earlier," Skrovonsky says.
The study also suggests that patients may not need monthly intravenous infusions of donanemab for life.
Patients were taken off the drug once the plaques in their brains were mostly gone, usually within a year. The plaques did not reappear during the 18-month study, and the benefit to memory and thinking continued.
That appears to give donanemab an edge over Leqembi, which requires ongoing treatment. But it's still not clear whether donanemab's benefits will persist for years after treatment ends.
"I imagine in the future we'll have this initiation phase where we knock down plaque and then we'll have maintenance therapy," Sperling says.
Both donanemab and Leqembi can cause dangerous swelling or bleeding in the brain.
In the donanemab study, brain scans revealed this side effect in about 25% of patients. About 6% had symptoms, like headache, nausea, and confusion. Three patients died.
A new era for Alzheimer's treatment?
The results with both donanemab and Leqembi provide strong evidence that removing amyloid from the brain can slow down Alzheimer's. That approach, known as the amyloid hypothesis, had been in doubt after dozens of other amyloid drugs failed to help patients.
One reason for the recent success is earlier treatment, Sperling says. Instead of treating patients who've already sustained significant brain damage from Alzheimer's, researchers have focused on people whose brains are still relatively healthy.
Another factor is the way researchers are approaching treatment, Sperling says.
"We've learned to be more aggressive with dosing," she says, which quickly reduces amyloid to very low levels in the brain.
But scientists still aren't sure which forms of amyloid offer the best target.
Single amyloid molecules appear to be harmless. But scientists have learned that when these molecules begin to clump together, they can take on forms that are toxic. Eventually, these clumps end up in plaques between brain cells.
"There's been a debate in our field for 30 years now about whether the plaques themselves are causing the problem," Sperling says. And the results with donanemab and leqembi are unlikely to end that debate.
Donanemab is designed to target plaques specifically. Leqembi is designed to target other forms of amyloid, though it also removes plaques.
Yet both drugs appear to slow down the loss of memory and thinking, in patients with early Alzheimer's.
A study Sperling is involved in could help answer the amyloid question by treating people who still have very little plaque in their brains.
"If we see benefit even at that stage," Sperling says, "one might argue it's not just plaque" eroding memory and thinking.
veryGood! (34)
Related
- Are Instagram, Facebook and WhatsApp down? Meta says most issues resolved after outages
- Costco recalls roughly 48,000 mattresses after over 500 customers report mold growth
- Miami Dolphins stop short of NFL scoring record with 70-point outburst – and fans boo
- Third Republican presidential debate to be held in Miami on Nov. 8
- SFO's new sensory room helps neurodivergent travelers fight flying jitters
- California Gov. Gavin Newsom signs bills to enhance the state’s protections for LGBTQ+ people
- Deion Sanders' message after Colorado's blowout loss at Oregon: 'You better get me right now'
- Happy Bruce Springsteen Day! The Boss turns 74 as his home state celebrates his birthday
- IRS recovers $4.7 billion in back taxes and braces for cuts with Trump and GOP in power
- The Halloween Spirit: How the retailer shows up each fall in vacant storefronts nationwide
Ranking
- Chuck Scarborough signs off: Hoda Kotb, Al Roker tribute legendary New York anchor
- Rep. Andy Kim announces bid for Robert Menendez's Senate seat after New Jersey senator's indictment
- Why the US job market has defied rising interest rates and expectations of high unemployment
- QB Joe Burrow’s status unclear as Rams and Bengals meet for first time since Super Bowl 56
- Nearly half of US teens are online ‘constantly,’ Pew report finds
- Biden tells Zelenskyy U.S. will provide Ukraine with ATACMS long-range missiles
- Thousands flee disputed enclave in Azerbaijan after ethnic Armenians laid down arms
- 1st and Relationship Goals: Inside the Love Lives of NFL Quarterbacks
Recommendation
The White House is cracking down on overdraft fees
Toddler and 2 adults fatally shot in Florida during argument over dog sale, authorities say
Murder charges dropped after fight to exonerate Georgia man who spent 22 years behind bars
After lots of interest in USWNT job, US Soccer zeroing in on short list for new coach
A White House order claims to end 'censorship.' What does that mean?
Young climate activists challenging 32 governments to get their day in court
A Black student was suspended for his hairstyle. Now, his family is suing Texas officials.
Hazing lawsuit filed against University of Alabama fraternity